ReverseScreen

Given a molecule, the targets it might interact with

Docking one compound into every characterized binding site answers the reverse screening question directly and takes 40.5 hours. A pharmacophore retrieval step in front of the docking cuts the panel to tens of proteins in 44 milliseconds, and the docking then runs only on what retrieval returns.

Screen a molecule How it works
Figure 1. One molecule, end to end. Orforglipron enters as a SMILES string and leaves as a ranked target with a pose that can be inspected. Panels A to F are the screen itself: a two-dimensional structure becomes 2,059 network inputs, PharmCast predicts all 10,549 pharmacophore bits without generating a conformer, and the 1,589 set bits are compared against every indexed co-crystal ligand. UK1 comes back first at a Tanimoto of 0.901 out of 27,797 ligands, and the index carries it through PDB entry 6X19 to the GLP-1 receptor. Panels G to I are the optional docking that follows: the retrieved ligand defines the site, the query is given a conformer, prepared and docked, and the returned pose is inspected against the deposited one. Every number shown is computed from the shipped model and the shipped index. Select the figure to open it at full size.
The reverse screen, drawn to the reduction it achieves STAGE 1 Query ligand one structure STAGE 2 Pharmacophore index 27,970 ligands 28,670 target sites STAGE 3 Retrieved sites 21.1 sites 108 s of docking STAGE 4 Ranked poses a handful inspect PharmCast, 4 ms search, 40 ms Vina, 5.1 s per site band height is the number of sites still in play, log scaled
Figure 2. The reverse screen. Band height is the number of receptor sites still in play at each stage, log scaled. Retrieval removes 99.9 percent of the panel in 44 milliseconds, which is what leaves docking a panel it can finish.

The question, and why the panel has stayed small

A screening campaign asks which of many ligands bind one target. The reverse question asks which of many targets bind one ligand. It is the question that arises once a molecule exists: what else does it hit, what explains a phenotype, what accounts for a toxicity, and what could the compound be repurposed against. It is also the only question available for a molecule a generative method proposes, because a designed structure has no measured target at all.

Inverse docking answers it by docking the ligand into a panel of pockets and ranking the panel. The panels have stayed small because the cost is linear in the panel size. On twenty performance cores, AutoDock Vina at exhaustiveness 16 takes 5.1 seconds for a drug-sized ligand, so a panel of 60 sites is five minutes and the 28,670 sites indexed here are 40.6 hours for a single molecule.

The ligand-based answer is cheap: chemically similar molecules tend to bind the same proteins, so a target can be predicted by similarity to annotated ligands. That returns a protein name. A name cannot be inspected, scored, or optimized against.

The two are better used in series than treated as alternatives. A ligand that resembles a molecule someone has already crystallized is likely to bind where that molecule binds, so the crystallographic record narrows the panel before any docking is attempted.

Four stages, and only the last is expensive

Stage 1

Index

Every co-crystal ligand in the Protein Data Bank, carrying the UniProt accessions it was solved against.

Fingerprinted in 29 s
Stage 2

Retrieve

Fingerprint the query, compare it to every indexed ligand, pool the proteins its nearest neighbors were crystallized against.

44 ms
Stage 3

Dock

AutoDock Vina into each retrieved site, in a box drawn around that site's own ligand envelope.

5.1 s per site
Stage 4

Inspect

Read the surviving poses in three dimensions, with the score and the burial of each.

A handful of poses

The fingerprint is predicted, not computed from conformers

Both sides of every comparison are the same calculation. The query and each of the 27,970 indexed ligands are predicted from two-dimensional structure by PharmCast, which returns a three-point pharmacophore fingerprint 10,549 bits wide without generating a conformer ensemble. That is what makes the query side take 4 milliseconds, and it is why a query can be compared against the whole index rather than against cluster representatives.

The search itself is exhaustive. All 10,549 bits are compared by Tanimoto over packed bit vectors against all 27,970 indexed ligands, with no folding, no hashing, no dimensionality reduction and no approximate nearest neighbor structure. The scan takes 40 milliseconds and has no parameter that could be tuned to flatter a benchmark.

Figure 3. The retrieval index in three dimensions. One point per indexed co-crystal ligand, embedded by UMAP directly from the full 10,549-bit fingerprints under Jaccard distance, which on binary vectors is the Tanimoto coefficient retrieval uses. Nothing is reduced or compressed first, so the distances drawn here are the distances the search computes. Points are colored by the target class the ligand was solved against. Orforglipron and daraxonrasib are ringed and labeled, each joined to the indexed ligand that carried its true target. Drag to rotate, scroll to zoom. The embedding is a navigational aid.

Retrieval and site comparison admit structures under different rules

Describing the atoms that line a pocket needs coordinates good enough to place every one of them, and the rule for that work is X-ray at 1.8 angstroms with a free R factor at or below 0.23. Establishing which ligand sat in which protein needs none of it: a 3.1 angstrom cryo-EM map answers that perfectly well. Retrieval therefore admits X-ray at 2.5 angstroms with a free R factor at or below 0.28, and cryo-EM at 4.0 angstroms, in both cases carrying a component of 250 to 900 daltons. Enumerating the archive under those two rules gives 61,935 X-ray entries and 12,620 cryo-EM entries.

Separating the two rules took coverage from 3,670 target sites to 28,579, an increase of 7.8 fold, and the gain falls on the receptors and large complexes solved by cryo-EM. The glucagon-like peptide 1 receptor is the clearest case: it carries 31 entries holding a drug-like ligand and not one of them satisfies the 1.8 angstrom rule, so under that rule the receptor is absent from the panel and no amount of searching can return it.

The archive behind the index is not standing still. The qualifying share of new releases has risen over the past decade, from 27.7 percent in 2016 to 36.4 percent in 2025, fluctuating from year to year within that rise. What the method depends on is the supply, and it is steady: about 113 entries a week now meet the admission rule. The Protein Data Bank releases once a week, on Wednesday, and the index is rebuilt every Thursday morning, so a release is searchable the next day.

Figure 4. The archive supplies new co-complexes every week. Entries released by the RCSB Protein Data Bank, counted by initial release date and queried on 8 September 2026. Left, annual release volume. Right, the same three series by quarter since the start of 2025. All released entries is every experimental entry. Protein-ligand co-complexes are entries with a polymer entity mapped to a UniProt accession that carry a chemical component of formula weight 250 to 900 daltons. Index-qualifying entries are that subset meeting the admission rule above. The qualifying share of new releases rose from 27.7 percent in 2016 to 36.4 percent in 2025. It fluctuates from year to year within that rise, and the 2026 projection is below 2025 on both filtered series. Open markers are projections from the elapsed fraction of the period. Select the figure to open it at full size.

What it costs and what it finds

Three thousand molecules were held out and screened. Each query was removed from the index by InChIKey connectivity layer first, so a molecule that had itself been deposited could not retrieve its own target through its own deposition. The question asked of each pool is whether the molecule's known target is inside it.

Nearest ligands pooledProteins in the poolFraction finding the targetDocking timeAgainst all 28,579
13.10.36316 s9,214 fold less
521.10.488108 s1,353 fold less
1044.40.5383.8 min643 fold less
25104.50.6088.9 min274 fold less
50186.30.66115.8 min153 fold less
100344.30.70829.3 min83 fold less
200598.50.76450.9 min48 fold less
4001,001.50.8151.42 h29 fold less

Pooling more neighbors buys accuracy and costs docking, and the exchange is steep at both ends: one neighbor docks 3.1 proteins and finds the target 36.3 percent of the time, four hundred docks 1,001.5 and finds it 81.5 percent. The operating point is set by the docking budget, and it is not one number. A single molecule can afford the pool that reaches 0.815, which is 1.42 hours on twenty cores. A library of 100,000 molecules cannot. Five neighbors is therefore the setting recommended for a library, at 21.1 proteins and about two minutes of docking, and 400 the setting for a single molecule run on its own, which is the default on the screening page.

Retrieval alone runs at library scale

Run in batches on a single core the retrieval stage averages 37.3 milliseconds per molecule, which is about 96,000 an hour and roughly 2.3 million in a day. A generative run can therefore be triaged in full, with docking spent only on what survives.

Docking finds the pose more often than it ranks it first

Thirty eight complexes were redocked into their own receptors, with the deposited pose discarded and a fresh conformer generated, so nothing but the location of the site reaches the docker. A pose counts as correct within 2.00 angstroms of the deposited coordinates.

Over 38 complexesCount
Search generates a correct pose27
Scoring puts it first14
Scoring puts it in the first three23

Sampling is ahead of scoring at this scale, which is why the poses come back for inspection rather than as a single number. Every pose is also rescored with the Vinardo function and the pool re-ranked by Vinardo alone and by the mean of the two ranks. Neither improves on Vina at the top of the list. Vinardo puts the correct pose first in 12 and within the first three in 24, and the mean of the two ranks gives 14 and 24. What pays instead is carrying the first three poses forward rather than the first, which raises the correct pose from 14 to 23 of the 27 the search finds, and costs nothing extra because the pool is already small.

Two 2025 clinical molecules

Both are themselves deposited, so both were removed from the index before their own query ran. Each found its target through a different molecule.

MoleculeTrue targetRank of 27,797Retrieved throughSimilarity
OrforglipronGlucagon-like peptide 1 receptor1component UK10.901
DaraxonrasibKRAS and cyclophilin A tri-complex4component A1AOI0.836

Daraxonrasib is the harder of the two and shows what the site definition has to carry. Its site is an interface between two proteins rather than a pocket in either one, deposited as the tri-complex at 1.65 angstroms. Docking it into KRAS alone cannot reproduce the binding, because half the site is missing.

Paper

Muskal, S. M. and Nicola, G. ReverseScreen.ai: Pharmacophore-Guided Reverse Screening Across the Growing Co-Complex Proteome. bioRxiv, first posted 15 September 2026, version 1. doi: 10.64898/2026.09.09.750461. CC BY 4.0.

The overview, in video. Reverse Screen: Given One Molecule, Which Proteins Does It Bind? 40 Hours of Docking to 108 Seconds

The fingerprint both sides of every comparison are made with: Muskal, S. M. and McGregor, M. J. PharmCast: rapid generation of three-dimensional pharmacophore fingerprints from two-dimensional structure without conformer generation. bioRxiv, 2026. doi: 10.64898/2026.09.02.748999